차바이오그룹 뉴스룸

• The only Korean company among 14 selected organizations from the U.S., UK, Japan, and other countries
• Opens new opportunities to supply Lipo-pam™ to global vaccine developers and research institutions
• “A significant international recognition of Lipo-pam™’s excellence and safety”

CHA Vaccine Institute (KOSDAQ: 261780) announced that its proprietary adjuvant, Lipo-pam™, has been officially included in the “Vaccine Adjuvant Library” established by the Coalition for Epidemic Preparedness Innovations (CEPI).

CEPI selected the adjuvants to ensure that the library holds a diverse class of adjuvants based on their stage of development with the potential to be produced at scale for vaccine distribution in low- and middle-income countries. Among 14 organizations—including multinational companies, government agencies, and biotech firms—from the United States, Japan, the United Kingdom, Canada, and China, Denmark and India, CHA Vaccine Institute is currently the only Korean company selected.

Since 2022, CEPI has been advancing its flagship “100Days Mission”, aimed at developing new vaccines within 100 days against a new viral threat with pandemic potential. To achieve this goal, CEPI is establishing a global pre-positioned infrastructure of vaccine candidates, platforms, adjuvants and other tools, to ready the world for a future viral threat.

A core part of this infrastructure is the Vaccine Adjuvant Library, hosted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). It will offer 25 carefully selected adjuvants to CEPI-supported vaccine developers, acting as a crucial “matching platform” to identify optimal adjuvant–vaccine combinations and accelerate vaccine development timelines. The service may expand more widely to other vaccine developers in the future.

The inclusion of Lipo-pam™ represents more than a technical milestone; it positions CHA Vaccine Institute as a strategic partner in the global vaccine ecosystem. Through the Adjuvant Library, CEPI-supported laboratories will assess pairings of vaccine candidates with adjuvants like Lipo-pam™, selected by the vaccine developer, in preclinical testing.  The developer can then leverage these data to proceed the successful vaccine-adjuvant pairing into clinical testing. This could increase CHA’s potential for participation in CEPI-supported joint development projects against emerging infectious diseases.

Building on this achievement, CHA Vaccine Institute plans to pursue multi-faceted growth. This includes expanding global partnerships, exploring technology transfer opportunities, and strengthening pandemic preparedness capabilities. Leveraging its immune-adjuvant platform, the company is also advancing potential development opportunities such as RSV (Respiratory Syncytial Virus) vaccines, cancer vaccines, and COVID–Influenza combination vaccines, to solidify its position within the global vaccine network.

“This inclusion is a meaningful international recognition of Lipo-pam™’s excellence a meaningful international recognition of Lipo-pam’s potential,” said Seungil Han, the CEO of CHA Vaccine Institute, “We look forward to active collaboration with global vaccine developers so that Lipo-pam™ can be widely utilized as an adjuvant in future pandemic responses.”

“Immune-boosting adjuvants have played a powerful role in transforming our response to deadly diseases over the past century. Yet, the COVID-19 pandemic shone a light on the challenges in accessing these vital ingredients, with the rights to adjuvants used in licensed COVID-19 vaccines held by only a handful of companies” explains Dr Richard Hatchett, CEO of CEPI. “Constrained supplies can result in an adjuvant getting paired with a vaccine based on what’s available at the time rather than what works best. This world-first library will fill the gap by matchmaking vaccines to a range of adjuvants to more rapidly identify the best combinations that could save lives and even stop a future pandemic in its tracks.” CEPI is a global partnership launched at the World Economic Forum in Davos in 2017 to accelerate the development of vaccines against epidemic and pandemic threats. It is supported by global foundations such as the Gates Foundation and the Wellcome Trust, as well as by funding from the governments of the Republic of Korea, Norway, the U.K., Germany, Japan, Canada, and others.#

*About CHA Vaccine Institute
CHA Vaccine Institute possesses proprietary adjuvant platform technologies. Its in-house developed adjuvants, L-pampo™ and Lipo-pam™, are TLR2/3-based adjuvants that maximize immune cell activation, enhancing the efficacy of vaccines and various immunotherapies. Using its adjuvant platform, the company has completed Phase 1 and Phase 2 clinical trials for a therapeutic hepatitis B vaccine and a prophylactic shingles vaccine.

*What is an Adjuvant?
An adjuvant is a substance that enhances the immune response to an antigen and is primarily used in recombinant protein vaccines. While recombinant protein vaccines offer high safety by not injecting the antigen directly, they typically have lower immunogenicity compared to traditional vaccines. Adjuvants are added to such vaccines to boost their immunogenicity.